BioSyent Hikes Quarterly Dividend 10% for First Quarter 2026

Biosyent ( (TSE:RX) ) has issued an announcement.

BioSyent Inc. has declared a first quarter 2026 dividend of $0.055 per common share, payable on March 13, 2026 to shareholders of record as of February 27, 2026, marking a 10% increase over the prior quarter’s dividend and qualifying as an eligible dividend for Canadian tax purposes. The move underscores the company’s continued profitability and shareholder-return focus, with dividend decisions remaining at the discretion of the board, and comes as BioSyent reports 11,263,255 common shares outstanding, highlighting a stable capital base for investors.

The most recent analyst rating on (TSE:RX) stock is a Buy with a C$14.00 price target. To see the full list of analyst forecasts on Biosyent stock, see the TSE:RX Stock Forecast page.

Spark’s Take on TSE:RX Stock

According to Spark, TipRanks’ AI Analyst, TSE:RX is a Outperform.

Biosyent’s overall stock score is driven by strong financial performance and positive technical indicators. The company’s robust revenue growth and profitability, combined with a positive market trend, support a favorable outlook. However, valuation metrics suggest the stock is fairly priced, and potential overbought conditions warrant caution.

To see Spark’s full report on TSE:RX stock, click here.

More about Biosyent

BioSyent Inc., listed on the TSX Venture Exchange under the symbol RX, is a profitable, growth-oriented specialty pharmaceutical company that focuses on in-licensing or acquiring innovative, proven healthcare and pharmaceutical products. The company markets these products through its community, specialty, and international business units, supporting healthcare professionals treating patients with safe and effective therapies.

Average Trading Volume: 3,470

Technical Sentiment Signal: Buy

Current Market Cap: C$150M

Learn more about RX stock on TipRanks’ Stock Analysis page.